Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 11, 2007

Nanogen Gains Access to Schizophrenia Markers

  • Nanogen acquired rights to genetic markers related to schizophrenia and responses to antipsychotic therapies from the Co-operative Research Centre for Diagnostics and Queensland University of Technology in Australia.

    Nanogen plans to utilize the markers to create diagnostic tests. Some of these markers may also help predict adverse drug reactions and therefore guide therapeutic decision-making.

    "Due to its complexity—schizophrenia, like many mental disorders, is believed to be caused by mutations in multiple genes— development of effective diagnostics and treatments is likely to require multiplexed analytic methods capable of examining multiple genes simultaneously," remarks David Ludvigson, Nanogen's president and COO.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »